Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-05-09 3:23 pm Purchase | 2022-04-30 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 250,261 4.200% | 604 (+0.24%) | Filing History |
| 2022-04-18 3:56 pm Purchase | 2022-04-18 | 13G | OncoCyte Corporation OCX | Halle Special Situations Fund LLC | 356,473 6.000% | 356,473 (New Position) | Filing History |
| 2022-04-15 5:21 pm Purchase | 2022-04-13 | 13D | OncoCyte Corporation OCX | Broadwood Partners, L.P. | 1,188,748 19.990% | 296,969 (+33.30%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 249,657 5.400% | 69,906 (+38.89%) | Filing History |
| 2021-09-24 4:40 pm Unchanged | 2021-09-23 | 13D | OncoCyte Corporation OCX | Broadwood Partners, L.P. | 891,780 19.300% | 0 (Unchanged) | Filing History |
| 2021-02-10 3:04 pm Purchase | 2021-01-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 179,752 4.600% | 4,650 (+2.66%) | Filing History |
| 2021-02-09 5:10 pm Purchase | 2021-02-05 | 13D | OncoCyte Corporation OCX | Broadwood Partners, L.P. | 891,780 20.100% | 30,000 (+3.48%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 175,102 5.200% | 175,102 (New Position) | Filing History |